Copyright Reports & Markets. All rights reserved.

Global Bipolar Disorder Medications Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Bipolar Disorder Medications
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Bipolar Disorder Medications Consumption Value by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Mood Stabilizers
    • 1.3.3 Anticonvulsants
    • 1.3.4 Antipsychotic Drugs
    • 1.3.5 Antidepressant Drugs
    • 1.3.6 Anti-Anxiety Drugs
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Bipolar Disorder Medications Consumption Value by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Hospital
    • 1.4.3 Clinic
  • 1.5 Global Bipolar Disorder Medications Market Size & Forecast
    • 1.5.1 Global Bipolar Disorder Medications Consumption Value (2018 & 2022 & 2029)
    • 1.5.2 Global Bipolar Disorder Medications Sales Quantity (2018-2029)
    • 1.5.3 Global Bipolar Disorder Medications Average Price (2018-2029)

2 Manufacturers Profiles

  • 2.1 AbbVie Inc.
    • 2.1.1 AbbVie Inc. Details
    • 2.1.2 AbbVie Inc. Major Business
    • 2.1.3 AbbVie Inc. Bipolar Disorder Medications Product and Services
    • 2.1.4 AbbVie Inc. Bipolar Disorder Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 AbbVie Inc. Recent Developments/Updates
  • 2.2 Glaxo SmithKline (GSK)
    • 2.2.1 Glaxo SmithKline (GSK) Details
    • 2.2.2 Glaxo SmithKline (GSK) Major Business
    • 2.2.3 Glaxo SmithKline (GSK) Bipolar Disorder Medications Product and Services
    • 2.2.4 Glaxo SmithKline (GSK) Bipolar Disorder Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Glaxo SmithKline (GSK) Recent Developments/Updates
  • 2.3 Eli Lily and Company
    • 2.3.1 Eli Lily and Company Details
    • 2.3.2 Eli Lily and Company Major Business
    • 2.3.3 Eli Lily and Company Bipolar Disorder Medications Product and Services
    • 2.3.4 Eli Lily and Company Bipolar Disorder Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Eli Lily and Company Recent Developments/Updates
  • 2.4 Janssen Pharmaceuticals
    • 2.4.1 Janssen Pharmaceuticals Details
    • 2.4.2 Janssen Pharmaceuticals Major Business
    • 2.4.3 Janssen Pharmaceuticals Bipolar Disorder Medications Product and Services
    • 2.4.4 Janssen Pharmaceuticals Bipolar Disorder Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Janssen Pharmaceuticals Recent Developments/Updates
  • 2.5 Johnson & Johnson
    • 2.5.1 Johnson & Johnson Details
    • 2.5.2 Johnson & Johnson Major Business
    • 2.5.3 Johnson & Johnson Bipolar Disorder Medications Product and Services
    • 2.5.4 Johnson & Johnson Bipolar Disorder Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Johnson & Johnson Recent Developments/Updates
  • 2.6 Astellas Pharma Inc
    • 2.6.1 Astellas Pharma Inc Details
    • 2.6.2 Astellas Pharma Inc Major Business
    • 2.6.3 Astellas Pharma Inc Bipolar Disorder Medications Product and Services
    • 2.6.4 Astellas Pharma Inc Bipolar Disorder Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Astellas Pharma Inc Recent Developments/Updates
  • 2.7 Bristol Myers Squibb
    • 2.7.1 Bristol Myers Squibb Details
    • 2.7.2 Bristol Myers Squibb Major Business
    • 2.7.3 Bristol Myers Squibb Bipolar Disorder Medications Product and Services
    • 2.7.4 Bristol Myers Squibb Bipolar Disorder Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Bristol Myers Squibb Recent Developments/Updates
  • 2.8 Gedeon Richter PLC.
    • 2.8.1 Gedeon Richter PLC. Details
    • 2.8.2 Gedeon Richter PLC. Major Business
    • 2.8.3 Gedeon Richter PLC. Bipolar Disorder Medications Product and Services
    • 2.8.4 Gedeon Richter PLC. Bipolar Disorder Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Gedeon Richter PLC. Recent Developments/Updates
  • 2.9 H. Lundbeck A/S
    • 2.9.1 H. Lundbeck A/S Details
    • 2.9.2 H. Lundbeck A/S Major Business
    • 2.9.3 H. Lundbeck A/S Bipolar Disorder Medications Product and Services
    • 2.9.4 H. Lundbeck A/S Bipolar Disorder Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 H. Lundbeck A/S Recent Developments/Updates
  • 2.10 Pfizer Inc.
    • 2.10.1 Pfizer Inc. Details
    • 2.10.2 Pfizer Inc. Major Business
    • 2.10.3 Pfizer Inc. Bipolar Disorder Medications Product and Services
    • 2.10.4 Pfizer Inc. Bipolar Disorder Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Pfizer Inc. Recent Developments/Updates
  • 2.11 Novartis AG
    • 2.11.1 Novartis AG Details
    • 2.11.2 Novartis AG Major Business
    • 2.11.3 Novartis AG Bipolar Disorder Medications Product and Services
    • 2.11.4 Novartis AG Bipolar Disorder Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Novartis AG Recent Developments/Updates
  • 2.12 Otsuka Holdings Co. Ltd
    • 2.12.1 Otsuka Holdings Co. Ltd Details
    • 2.12.2 Otsuka Holdings Co. Ltd Major Business
    • 2.12.3 Otsuka Holdings Co. Ltd Bipolar Disorder Medications Product and Services
    • 2.12.4 Otsuka Holdings Co. Ltd Bipolar Disorder Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Otsuka Holdings Co. Ltd Recent Developments/Updates
  • 2.13 Validus Pharmaceuticals LLC.
    • 2.13.1 Validus Pharmaceuticals LLC. Details
    • 2.13.2 Validus Pharmaceuticals LLC. Major Business
    • 2.13.3 Validus Pharmaceuticals LLC. Bipolar Disorder Medications Product and Services
    • 2.13.4 Validus Pharmaceuticals LLC. Bipolar Disorder Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Validus Pharmaceuticals LLC. Recent Developments/Updates

3 Competitive Environment: Bipolar Disorder Medications by Manufacturer

  • 3.1 Global Bipolar Disorder Medications Sales Quantity by Manufacturer (2018-2023)
  • 3.2 Global Bipolar Disorder Medications Revenue by Manufacturer (2018-2023)
  • 3.3 Global Bipolar Disorder Medications Average Price by Manufacturer (2018-2023)
  • 3.4 Market Share Analysis (2022)
    • 3.4.1 Producer Shipments of Bipolar Disorder Medications by Manufacturer Revenue ($MM) and Market Share (%): 2022
    • 3.4.2 Top 3 Bipolar Disorder Medications Manufacturer Market Share in 2022
    • 3.4.2 Top 6 Bipolar Disorder Medications Manufacturer Market Share in 2022
  • 3.5 Bipolar Disorder Medications Market: Overall Company Footprint Analysis
    • 3.5.1 Bipolar Disorder Medications Market: Region Footprint
    • 3.5.2 Bipolar Disorder Medications Market: Company Product Type Footprint
    • 3.5.3 Bipolar Disorder Medications Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Bipolar Disorder Medications Market Size by Region
    • 4.1.1 Global Bipolar Disorder Medications Sales Quantity by Region (2018-2029)
    • 4.1.2 Global Bipolar Disorder Medications Consumption Value by Region (2018-2029)
    • 4.1.3 Global Bipolar Disorder Medications Average Price by Region (2018-2029)
  • 4.2 North America Bipolar Disorder Medications Consumption Value (2018-2029)
  • 4.3 Europe Bipolar Disorder Medications Consumption Value (2018-2029)
  • 4.4 Asia-Pacific Bipolar Disorder Medications Consumption Value (2018-2029)
  • 4.5 South America Bipolar Disorder Medications Consumption Value (2018-2029)
  • 4.6 Middle East and Africa Bipolar Disorder Medications Consumption Value (2018-2029)

5 Market Segment by Type

  • 5.1 Global Bipolar Disorder Medications Sales Quantity by Type (2018-2029)
  • 5.2 Global Bipolar Disorder Medications Consumption Value by Type (2018-2029)
  • 5.3 Global Bipolar Disorder Medications Average Price by Type (2018-2029)

6 Market Segment by Application

  • 6.1 Global Bipolar Disorder Medications Sales Quantity by Application (2018-2029)
  • 6.2 Global Bipolar Disorder Medications Consumption Value by Application (2018-2029)
  • 6.3 Global Bipolar Disorder Medications Average Price by Application (2018-2029)

7 North America

  • 7.1 North America Bipolar Disorder Medications Sales Quantity by Type (2018-2029)
  • 7.2 North America Bipolar Disorder Medications Sales Quantity by Application (2018-2029)
  • 7.3 North America Bipolar Disorder Medications Market Size by Country
    • 7.3.1 North America Bipolar Disorder Medications Sales Quantity by Country (2018-2029)
    • 7.3.2 North America Bipolar Disorder Medications Consumption Value by Country (2018-2029)
    • 7.3.3 United States Market Size and Forecast (2018-2029)
    • 7.3.4 Canada Market Size and Forecast (2018-2029)
    • 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

  • 8.1 Europe Bipolar Disorder Medications Sales Quantity by Type (2018-2029)
  • 8.2 Europe Bipolar Disorder Medications Sales Quantity by Application (2018-2029)
  • 8.3 Europe Bipolar Disorder Medications Market Size by Country
    • 8.3.1 Europe Bipolar Disorder Medications Sales Quantity by Country (2018-2029)
    • 8.3.2 Europe Bipolar Disorder Medications Consumption Value by Country (2018-2029)
    • 8.3.3 Germany Market Size and Forecast (2018-2029)
    • 8.3.4 France Market Size and Forecast (2018-2029)
    • 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
    • 8.3.6 Russia Market Size and Forecast (2018-2029)
    • 8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

  • 9.1 Asia-Pacific Bipolar Disorder Medications Sales Quantity by Type (2018-2029)
  • 9.2 Asia-Pacific Bipolar Disorder Medications Sales Quantity by Application (2018-2029)
  • 9.3 Asia-Pacific Bipolar Disorder Medications Market Size by Region
    • 9.3.1 Asia-Pacific Bipolar Disorder Medications Sales Quantity by Region (2018-2029)
    • 9.3.2 Asia-Pacific Bipolar Disorder Medications Consumption Value by Region (2018-2029)
    • 9.3.3 China Market Size and Forecast (2018-2029)
    • 9.3.4 Japan Market Size and Forecast (2018-2029)
    • 9.3.5 Korea Market Size and Forecast (2018-2029)
    • 9.3.6 India Market Size and Forecast (2018-2029)
    • 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
    • 9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

  • 10.1 South America Bipolar Disorder Medications Sales Quantity by Type (2018-2029)
  • 10.2 South America Bipolar Disorder Medications Sales Quantity by Application (2018-2029)
  • 10.3 South America Bipolar Disorder Medications Market Size by Country
    • 10.3.1 South America Bipolar Disorder Medications Sales Quantity by Country (2018-2029)
    • 10.3.2 South America Bipolar Disorder Medications Consumption Value by Country (2018-2029)
    • 10.3.3 Brazil Market Size and Forecast (2018-2029)
    • 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

  • 11.1 Middle East & Africa Bipolar Disorder Medications Sales Quantity by Type (2018-2029)
  • 11.2 Middle East & Africa Bipolar Disorder Medications Sales Quantity by Application (2018-2029)
  • 11.3 Middle East & Africa Bipolar Disorder Medications Market Size by Country
    • 11.3.1 Middle East & Africa Bipolar Disorder Medications Sales Quantity by Country (2018-2029)
    • 11.3.2 Middle East & Africa Bipolar Disorder Medications Consumption Value by Country (2018-2029)
    • 11.3.3 Turkey Market Size and Forecast (2018-2029)
    • 11.3.4 Egypt Market Size and Forecast (2018-2029)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
    • 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

  • 12.1 Bipolar Disorder Medications Market Drivers
  • 12.2 Bipolar Disorder Medications Market Restraints
  • 12.3 Bipolar Disorder Medications Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry
  • 12.5 Influence of COVID-19 and Russia-Ukraine War
    • 12.5.1 Influence of COVID-19
    • 12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Bipolar Disorder Medications and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Bipolar Disorder Medications
  • 13.3 Bipolar Disorder Medications Production Process
  • 13.4 Bipolar Disorder Medications Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Bipolar Disorder Medications Typical Distributors
  • 14.3 Bipolar Disorder Medications Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Bipolar Disorder Medications market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    Drug therapy is currently the core method of treating bipolar disorder, that is, the use of emotional stabilizers to adjust the patient's mood. Bipolar disorder is complex and difficult to control. The drug effect of emotional stabilizers can help patients to suppress their emotions when they are too high, to increase their emotions when they are depressed, to stabilize their emotions at a normal level, and to effectively prevent the recurrence of bipolar disorder. The quickest and most effective approach may be convulsive-free electroconvulsive therapy.
    This report is a detailed and comprehensive analysis for global Bipolar Disorder Medications market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global Bipolar Disorder Medications market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
    Global Bipolar Disorder Medications market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
    Global Bipolar Disorder Medications market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
    Global Bipolar Disorder Medications market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Bipolar Disorder Medications
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Bipolar Disorder Medications market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie Inc., Glaxo SmithKline (GSK), Eli Lily and Company, Janssen Pharmaceuticals and Johnson & Johnson, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market Segmentation
    Bipolar Disorder Medications market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Mood Stabilizers
    Anticonvulsants
    Antipsychotic Drugs
    Antidepressant Drugs
    Anti-Anxiety Drugs
    Market segment by Application
    Hospital
    Clinic
    Major players covered
    AbbVie Inc.
    Glaxo SmithKline (GSK)
    Eli Lily and Company
    Janssen Pharmaceuticals
    Johnson & Johnson
    Astellas Pharma Inc
    Bristol Myers Squibb
    Gedeon Richter PLC.
    H. Lundbeck A/S
    Pfizer Inc.
    Novartis AG
    Otsuka Holdings Co. Ltd
    Validus Pharmaceuticals LLC.
    Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Bipolar Disorder Medications product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Bipolar Disorder Medications, with price, sales, revenue and global market share of Bipolar Disorder Medications from 2018 to 2023.
    Chapter 3, the Bipolar Disorder Medications competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Bipolar Disorder Medications breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
    Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Bipolar Disorder Medications market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
    Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Bipolar Disorder Medications.
    Chapter 14 and 15, to describe Bipolar Disorder Medications sales channel, distributors, customers, research findings and conclusion.

    Buy now